153 related articles for article (PubMed ID: 6167486)
21. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
Souness JE; Diocee BK; Martin W; Moodie SA
Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
[TBL] [Abstract][Full Text] [Related]
22. Dihydro- and tetrahydroisoquinolines as inhibitors of cyclic nucleotide phosphodiesterases from dog heart. Structure-activity relationships.
Van Inwegen RG; Salaman P; St Georgiev V; Weinryb I
Biochem Pharmacol; 1979 Apr; 28(8):1307-12. PubMed ID: 87199
[No Abstract] [Full Text] [Related]
23. Effects of divalent metals on the specificity of inhibitors of the cyclic nucleotide phosphodiesterases from bovine heart.
Donnelly TE; Barron B
Biochim Biophys Acta; 1981 Jan; 657(1):168-78. PubMed ID: 6260197
[TBL] [Abstract][Full Text] [Related]
24. Cyclic nucleotide phosphodiesterase assay technology.
MacKenzie SJ; Hastings SF; Wells C
Curr Protoc Pharmacol; 2010 Jun; Chapter 3():Unit 3.12. PubMed ID: 22294369
[TBL] [Abstract][Full Text] [Related]
25. Chromatographic behavior of cyclic 3',5'-nucleotide phosphodiesterases on columns of immobilized inhibitors.
Mohindru A; Chenet A; Rhoads AR
Biochemistry; 1978 Aug; 17(16):3297-304. PubMed ID: 80229
[No Abstract] [Full Text] [Related]
26. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
27. Assay of cyclic nucleotide phosphodiesterase using radiolabeled and fluorescent substrates.
Kincaid RL; Manganiello VC
Methods Enzymol; 1988; 159():457-70. PubMed ID: 2842611
[No Abstract] [Full Text] [Related]
28. Adrenal medullary cyclic nucleotide phosphodiesterase.--Regulatory properties of three enzyme activities.
Sitaramayya A; Campbell JA; Siegel FL
J Neurochem; 1978 Jun; 30(6):1281-5. PubMed ID: 209131
[No Abstract] [Full Text] [Related]
29. Stimulation of rat liver cyclic 3':5'-nucleotide phosphodiesterase by cyclic GMP is dependent on enzyme concentration.
Guan WR; Cheung WY
Arch Biochem Biophys; 1980 Oct; 204(1):191-8. PubMed ID: 6252844
[No Abstract] [Full Text] [Related]
30. Activation of human lymphocyte high affinity cyclic AMP phosphodiesterase by culture with 1-methyl-3-isobutylxanthine.
Thompson WJ; Ross CP; Hersh EM; Epstein PM; Strada SJ
J Cyclic Nucleotide Res; 1980; 6(1):25-36. PubMed ID: 6155390
[TBL] [Abstract][Full Text] [Related]
31. [Properties of cyclic nucleotide phosphodiesterase from lingual taste papillae].
Ostretsova IB
Biokhimiia; 1978 Jun; 43(6):1037-44. PubMed ID: 27246
[TBL] [Abstract][Full Text] [Related]
32. Functional identification of phosphodiesterase activity in human trabecular meshwork cells.
Zhou L; Thompson WJ; Potter DE
J Ocul Pharmacol Ther; 2000 Aug; 16(4):317-22. PubMed ID: 10977127
[TBL] [Abstract][Full Text] [Related]
33. Cyclic nucleotide phosphodiesterase activity: histochemical and cytochemical methods.
Ueno S; Ueck M
Methods Enzymol; 1988; 159():477-89. PubMed ID: 2842613
[No Abstract] [Full Text] [Related]
34. Phosphodiesterase inhibitors as tools in cyclic nucleotide research: a precautionary comment.
Wells JN; Kramer GL
Mol Cell Endocrinol; 1981 Jul; 23(1):1-9. PubMed ID: 6167475
[No Abstract] [Full Text] [Related]
35. Effects of phosphodiesterase inhibitors, imidazole and phosphate on cyclic CMP phosphodiesterase are different from those on cyclic AMP and cyclic GMP phosphodiesterases.
Kuo JF; Shoji M; Brackett NL; Helfman DM
J Cyclic Nucleotide Res; 1978 Dec; 4(6):463-74. PubMed ID: 85641
[TBL] [Abstract][Full Text] [Related]
36. Analysis of the relationship between pharmacological inhibition of cyclic nucleotide phosphodiesterase and relaxation of canine tracheal smooth muscle.
Polson JB; Krzanowski JJ; Anderson WH; Fitzpatrick DF; Hwang DP; Szentivanyi A
Biochem Pharmacol; 1979 Apr; 28(8):1391-5. PubMed ID: 87201
[No Abstract] [Full Text] [Related]
37. Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells.
Lugnier C; Schini VB
Biochem Pharmacol; 1990 Jan; 39(1):75-84. PubMed ID: 2153383
[TBL] [Abstract][Full Text] [Related]
38. Cyclic nucleotide phosphodiesterase in rat parotid gland.
Yokoyama N; Abe M; Furuyama S
Can J Physiol Pharmacol; 1981 Mar; 59(3):293-9. PubMed ID: 6261905
[TBL] [Abstract][Full Text] [Related]
39. The distribution of cyclic nucleotide phosphodiesterase in the hypothalamus.
Howlett AC; Breckenridge BM
J Neurochem; 1978 Jul; 31(1):321-7. PubMed ID: 209146
[No Abstract] [Full Text] [Related]
40. Antiplatelet effects of KW-7, a new inhibitor of cyclic nucleotide phosphodiesterases.
Wu CC; Wang WY; Kuo RY; Chang FR; Wu YC
Eur J Pharmacol; 2004 Jan; 483(2-3):187-94. PubMed ID: 14729106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
